Abstract

Abstract Tumor cells remodel their metabolism to meet their unique demands in order to support tumor growth and progression. However, this reprogramming may create metabolic vulnerabilities. The small molecule L-2-hdroxyglutarate (L-2HG) is commonly elevated in clear cell renal cell carcinoma (ccRCC). Similar to other small molecules elevated in cancer, L-2HG has the potential to regulate gene expression by altering DNA, histone, and/or RNA methylation. Using unbiased profiling methodologies, we find that L-2HG remodels tumoral metabolism in renal cancer cells through the combined effects on histone methylation and RNA N6-methyladenosine (m6A). The combined effects of L-2HG result in a serine liability that renders tumors cells reliant on exogenous serine to support in vitro/vivo tumor growth and redox balance. In agreement with these data, raised L-2HG kidney tumors have reduced expression of serine biosynthetic enzymes. In summary, our data reveal that high L-2HG kidney tumors could be targeted by strategies that limit the availability of this now "essential" amino acid. Citation Format: Sunil Sudarshan. Remodeling of tumor metabolism by L-2-hydroxyglutarate: Implications for renal cancer growth and progression [abstract]. In: Proceedings of the AACR Special Conference: Advances in Kidney Cancer Research; 2023 Jun 24-27; Austin, Texas. Philadelphia (PA): AACR; Cancer Res 2023;83(16 Suppl):Abstract nr IA016.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call